Tribal business settles Stanford opioid treatment clash

Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Indivior appeal fails to stop generic opioid addiction challenge

15 July 2019 The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

Americas

Stanford University enters licence agreement for EGF technology

5 January 2018 Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor wound healing technology.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Tribal business settles Stanford opioid treatment clash

More on this story

Editor's picks

Editor's picks

More features